QDEL · QuidelOrtho Corp · Investor Relations

QuidelOrtho has entered a long-term strategic supply agreement with Lifotronic Technology Co., Ltd. (Lifotronic Technology Co., Ltd., stock code: 688389), to expand QuidelOrtho's global immunoassay portfolio and accelerate customer access to scalable, high quality, cost-efficient solutions across select markets outside the United States. The agreement provides QuidelOrtho access to multiple high-throughput and low-to-mid volume immunoassay analyzer platforms, each supported by a broad menu of assays spanning routine and specialty testing. The collaboration is expected to expand QuidelOrtho's immunoassay menu with more than 25 new assays on these systems that are not currently available on the VITROS system, within a total menu of over 70 assays on these new partner platforms. These additions are planned to increase QuidelOrtho's ability to compete for full-menu tenders and serve a wider range of laboratory settings, from smaller laboratories seeking low-volume solutions to larger,

QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the fourth quarter and full-year ended December 28, 2025. "In 2025, we transitioned from COVID-driven volatility to a more durable, diversified diagnostics business," said Brian J. Blaser, President and Chief Executive Officer of QuidelOrtho. "Our Labs, Immunohematology and Cardiac businesses delivered consistent growth, while cost-savings initiatives drove meaningful margin expansion. As a result, we are well positioned to generate substantially stronger free cash flow in 2026, which we believe more accurately reflects the earnings power of our business." Key Fourth Quarter 2025 Results: (all comparisons are to the prior year period) Total revenue was $724 million, as reported Non-respiratory revenue of $600 million; excluding Donor Screening 1 , non-respiratory revenue grew 7% in constant currency. Labs revenue grew 8% as

QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho") received the Excellence Services Label for its Customer and Technical Services in EMEA, awarded by the independent association Esprit de Service France, and in accordance with the international standard ISO 23592, a global framework for designing and delivering outstanding customer experiences. QuidelOrtho is the first medical device company to receive this distinction. QuidelOrtho also won a Gold Stevie Award in the Customer Service Success category and a Bronze Stevie Award in the AI & Tech Focused Digital Transformation Team of the Year category in the 20th annual Stevie Awards for Sales & Customer Service. These awards underscore the customer experience at QuidelOrtho, which is designed to be predictive, connected, intelligent and grounded in the QuidelOrthoCQ™ Philosophy of turning intelligence and ease into care customers can feel. "These 2026 recognitions are a testament to the passion and discipline of our teams